Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AGMB

AgomAb Therapeutics NV ADR

May 01 • 04:00PM ET

11.19

+0.34 3.13 %

Healthcare • Biotechnology • Belgium • Small • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	48.74M	Perf Week	1.27%
Market Cap	545.40M	Forward P/E	-	EPS next Y	-2.15	Insider Trans	-	Shs Float	-	Perf Month	-5.01%
Enterprise Value	410.03M	PEG	-	EPS next Q	-0.43	Inst Own	1.45%	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	12.53%	Inst Trans	34.59%	Short Ratio	2.02	Perf Half Y	-
Sales	-	P/B	3.55	EPS next Y	-21.30%	ROA	-	Short Interest	0.43M	Perf YTD	-23.62%
Book/sh	3.15	P/C	3.99	EPS next 5Y	-5.72%	ROE	-	52W High	17.45 -35.88%	Perf Year	-
Cash/sh	2.81	P/FCF	-	EPS past 3/5Y	-102.05% -	ROIC	-	52W Low	9.00 24.33%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.42% 9.81%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.49	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.28	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.49	EPS Q/Q	-	SMA20	3.77%	Beta	-	Target Price	32.17
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-10.33%	Rel Volume	0.25	Prev Close	10.85
Employees	62	LT Debt/Eq	0.01	Earnings	Apr 23 AMC	SMA200	-13.38%	Avg Volume	214.94K	Price	11.19
IPO	Feb 06, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	-8.39% -	Trades		Volume	53,733	Change	3.13%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-03-26	Initiated	Morgan Stanley	Overweight	$28
Mar-03-26	Initiated	Leerink Partners	Outperform	$36
Mar-03-26	Initiated	JP Morgan	Overweight	$32

Apr-23-26 06:14PM	Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook (GlobeNewswire)
Mar-26-26 07:00AM	Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire) -7.70%
Feb-09-26 04:05PM	Agomab Announces Closing of Initial Public Offering (GlobeNewswire) +6.55%
Feb-07-26 10:55AM	Agomab indicated to open at $15.50, IPO priced at $16 (TipRanks)
Feb-05-26 07:24PM	Agomab Announces Pricing of Initial Public Offering (GlobeNewswire)

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AGMB

AgomAb Therapeutics NV ADR

Upgrade your Finviz experience